Core Viewpoint - The stock of HAPO Pharmaceutical-B (02142) has increased by over 4%, reaching HKD 14.22, with a trading volume of HKD 27.84 million, following the announcement of an updated global strategic collaboration with AstraZeneca [1] Group 1: Collaboration Details - HAPO Pharmaceutical announced an update to its global strategic collaboration with AstraZeneca, established in March 2025, focusing on the discovery and development of next-generation biotherapies, including antibody-drug conjugates (ADC) and T-cell engagers (TCE) [1] - Under the agreement, AstraZeneca will nominate R&D projects annually for the next four years, demonstrating the deepening of the partnership [1] - HAPO Pharmaceutical will be eligible to receive option fees, exercise fees, development and commercial milestone payments, as well as tiered royalties based on future net sales of the licensed projects, consistent with the financial framework established in March 2025 [1]
港股异动 | 和铂医药-B(02142)再涨超4% 与阿斯利康深化合作 共同研发新一代肿瘤生物疗法